Hussman Strategic Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Hussman Strategic Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-63,000	Closed	-$721K	–	249
2023 Q4	$721K	Sell	63,000 -61,000	-49%	-$603K	0.16%	170
2023 Q3	$1.19M	Hold	124,000	–	–	0.23%	174
2023 Q2	$1.32M	Sell	124,000 -32,000	-21%	-$344K	0.24%	185
2023 Q1	$1.64M	Hold	156,000	–	–	0.26%	163
2022 Q4	$1.93M	Hold	156,000	–	–	0.31%	128
2022 Q3	$1.62M	Hold	156,000	–	–	0.28%	147
2022 Q2	$1.8M	Buy	156,000 +104,000	+200%	+$1.23M	0.31%	120
2022 Q1	$654K	Sell	52,000 -26,000	-33%	-$298K	0.13%	227
2021 Q4	$909K	Buy	+78,000	New	+$957K	0.2%	160

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Hussman Strategic Advisors's IRWD Position: Q1 2024 in Review

Hussman Strategic Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2024, closing a stake of 63,000 shares — an estimated $721K sold.

Hussman Strategic Advisors first reported a position in IRWD in Q4 2021 and held it in 9 quarters. The position peaked at $1.93M in Q4 2022. 261 funds tracked by Wall St. Rank hold IRWD as of Q1 2024.

Hussman Strategic Advisors reported no remaining Ironwood Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Hussman Strategic Advisors sold 63,000 Ironwood Pharmaceuticals shares in Q1 2024, an estimated $721K.
Hussman Strategic Advisors first reported a position in Ironwood Pharmaceuticals in Q4 2021 and held it in 9 quarters.
Hussman Strategic Advisors's Ironwood Pharmaceuticals position peaked at $1.93M in Q4 2022.
261 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2024.

Based on Hussman Strategic Advisors's 13F filing for Q1 2024, filed 1 May 2024.